Press releases

Beactica to present at BioEquity Europe 2019

Beactica AB, the Swedish drug discovery company, today announced that it has been selected to present at the 20 th Annual BioEquity Europe 2019. The conference will take place on 20–21 May in Barcelona, Spain. Dr Per Källblad, Chief Executive Officer, to present on Monday 20 May 2019 at 2:20 PM. The location is the... [...]

Beactica, VIB and CD3 announce drug discovery alliance targeting inflammatory diseases

Beactica AB, the Swedish drug discovery company, today announced a new partnership with VIB and KU Leuven’s Centre for Drug Design and Discovery (CD3). The three parties will be working together in a drug discovery project to address critical unmet needs in the area of inflammation. The partnership goal is to generate... [...]

Beactica to present LSD1 programme at the AACR Annual Meeting 2019

Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2019. The conference will take place on 29 March – 3 April, 2019 at Georgia World Congress Center in Atlanta, USA. Dr Ulf... [...]

Beactica receives the Nordic Stars Award 2018

Beactica, the Swedish drug discovery company, today announced that it has been given the Nordic Stars Award 2018. The prize is handed out annually by SwedenBIO, the Swedish association for the life science industry, “ in special recognition of life science companies in the Nordic region demonstrating outstanding innovation... [...]

Beactica to present pipeline update at NLSDays

Beactica, the Swedish drug discovery company, today announced that it has been selected for a company presentation at NLSDays 2018 in Stockholm, on 11 th September. Per Källblad, CEO, will deliver an update on Beactica and its pipeline of novel cancer therapeutics during the first Pharmaceuticals Company Presentations... [...]

Beactica signs three-year extension agreement with Sanofi

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced that it has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions... [...]

Beactica signs five-year framework agreement with global pharmaceutical company

Beactica, the Swedish company with unique capabilities to evaluate the interactions of molecules, today announced that it has signed a five-year research services agreement with an undisclosed top-five-ranked global pharmaceutical company. The framework agreement outlines the legal terms under which Beactica will provide... [...]